Compared to Estimates, Pacific Biosciences (PACB) Q4 Earnings: A Look at Key Metrics

Core Insights - Pacific Biosciences of California (PACB) reported a revenue of $39.22 million for the quarter ended December 2024, reflecting a decline of 32.8$0.20, an improvement from -$0.27 in the same quarter last year [1] - The reported revenue slightly exceeded the Zacks Consensus Estimate of$39.2 million by 0.06%, while the EPS met the consensus estimate [1] Revenue Breakdown - Revenue from Product - Instrument was $15.30 million, falling short of the estimated$16.94 million by analysts, representing a year-over-year decline of 56.4% [4] - Revenue from Product was $34.10 million, below the estimated$36.10 million [4] - Revenue from Service and other was $5.13 million, surpassing the average estimate of$4.88 million, showing a year-over-year increase of 17.7% [4] - Revenue from Product - Consumable was $18.80 million, slightly below the estimated$19.17 million, with a year-over-year change of -0.5% [4] Stock Performance - Shares of Pacific Biosciences have decreased by 22.1% over the past month, contrasting with a 3.9% increase in the Zacks S&P 500 composite [3] - The stock currently holds a Zacks Rank 4 (Sell), indicating potential underperformance relative to the broader market in the near term [3]